Myocardial extracellular volume derived from contrast-enhanced chest computed tomography for longitudinal evaluation of cardiotoxicity in patients with breast cancer treated with anthracyclines

Figures

• 

  Fig. 1. Flow diagram of participants. CECT, contrast-enhanced computed tomography

• 

  Fig. 2. Region of interest for extracellular volume calculations on computed tomography in a 55-year-old woman with breast cancer. a Contrast-enhanced scan, the ROIs were manually delineated in the middle of the interventricular septum and blood pool avoiding the papillary muscle. b Unenhanced scan, copy the two ROIs in the contrast-enhanced image and place them at similar locations in the unenhanced ventricular septum and blood pool. ROI, region of interest

• 

  Fig. 3. The temporal changes and linear fitting of longitudinal changes of myocardial ECV of BC patients. CTRCD0, patients without cancer therapy-related cardiac dysfunction; CTRCD1, patients with cancer therapy-related cardiac dysfunction; ECV, myocardial extracellular volume; BC, breast cancer

• 

  Fig. 4. A 48-year-old BC patient without CTRCD (a, b, c, d) and a 52-year-old BC patient with CTRCD (e, f, g, h). The baseline ECV value before anthracycline chemotherapy in patient without CTRCD was 29.56% derived from unenhanced (a) and enhanced CT images (b). The ECV value after completing anthracycline chemotherapy was 30.00% derived from unenhanced (c) and enhanced CT images (d). The baseline ECV value before anthracycline chemotherapy in patient with CTRCD was 29.50% derived from unenhanced (e) and enhanced CT images (f). The ECV value after completing anthracycline chemotherapy was 34.68% derived from unenhanced (g) and enhanced CT images (h). BC, breast cancer; CTRCD, cancer therapy-related cardiac dysfunction; ECV, myocardial extracellular volume; CT, computed tomography